Menu
← Oncology Approval Tracker
FDA DECISION ·
Pluvicto
lutetium Lu 177 vipivotide tetraxetan · Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitor therapy who are appropriate candidates to delay taxane chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The decision brought PSMA-targeted radioligand treatment into a pre-taxane setting for eligible patients.
What research teams should watch
Coordinate PSMA imaging, nuclear medicine capacity, radiation handling, and timely referral from oncology.
Related study operations checklist
See the staffing responsibilities, timing, and handoff questions for this study setting.
PSMA-selected radioligand studiesPRIMARY RECORDS